Podcasts about Pfizer

Welcome to Episode 313 of Autism Parenting Secrets. This week I'm joined by attorney Aaron Siri, Managing Partner of Siri & Glimstad and author of the new book Vaccines, Amen. Aaron has spent more than a decade challenging government agencies, pharmaceutical companies, and public health institutions on issues related to medical freedom, informed consent, and transparency. In this conversation, we explore why vaccines are treated differently under the law than almost any other product, what Aaron discovered through years of litigation and public records requests, and why parents should understand the difference between scientific consensus and scientific evidence. Regardless of where you land on these issues, this discussion highlights the importance of critical thinking, asking better questions, and making informed decisions in a world where complex topics are often reduced to simple talking points. The secret this week is…  Consensus ISN'T The Same As Truth You'll Discover: Why one product is treated differently than almost every other product on the market (2:05) Why doing your own homework matters more than most parents realize (15:10) The difference between consensus and actual evidence (27:48) What a federal lawsuit revealed about the studies behind a major public health claim (33:36) Why informed consent requires the freedom to say no (38:20) About Our Guest: Aaron Siri is the author of Vaccines, Amen, host of the Informed w/ Aaron Siri podcast, and Managing Partner of Siri & Glimstad LLP, a national law firm focused on civil rights, constitutional law, and complex litigation. He has led numerous high-profile legal challenges involving medical mandates, government transparency, and informed consent, including efforts that resulted in the release of Pfizer's Covid-19 clinical trial documents and the restoration of vaccine exemptions affecting hundreds of thousands of students. Aaron is a graduate of UC Berkeley School of Law and is widely recognized for his work advancing informed consent, medical freedom, and government transparency. www.sirillp.com/aaron-siri/ References in this Episode: Vaccines, Amen by Aaron Siri Informed w/ Aaron Siri podcast Informed Consent Action Network (ICAN) Siri & Glimstad Additional Resources: To learn more about personalized 1:1 support go to www.elevatehowyounavigate.com If you enjoyed this episode, share it with your friends.

While Elsevier's most recent Clinician of the Future Report shows increasing adoption of artificial intelligence tools among physicians and nurses, and optimism that they will improve quality of care in the future, a majority raised concerns about trust and reliability. To increase the level of trust, 60% said transparent citations of evidence-based and peer-reviewed research will be key. How to provide that transparency is our focus today as Raise the Line host Lindsey Smith welcomes Elsevier colleagues Rhett Alden and Raman Kaur to guide us through the complexities involved, including the concept of traceability and what role it plays in how AI tools such as Elsevier's ClinicalKey AI are built and deployed.  “Traceability changes the confidence that a clinician has in an AI tool so that they aren't trusting the AI, they're trusting the underlying evidence they're consuming from the AI-assisted platform,” says Raman, who brings years of experience as a primary care practitioner to her work.  It's also important, Rhett adds, to provide additional information, pulled from both the clinician's query and the patient's medical record, to inform clinical thinking. “ClinicalKey AI can be more than a response engine by establishing a larger context to provide a more precise answer for that individual patient.” In this thought-provoking discussion, these experts also provide insights on: Mitigating bias in AI results; Using AI responsibly with sustainability in mind; What type of clinician will benefit most from AI Mentioned in this episode: ClinicalKey AI Clinician of the Future Report If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

John Prinz shares his story of replacing 1,100 mg/day OxyContin with medical cannabis, positioning him as an early "patient zero" in opioid-to-cannabis transition. A 1992 workplace injury at Simpson Paper in Anderson, CA led to five spinal surgeries, hardware implantation, and a spinal cord injury diagnosis, setting the foundation for extreme opioid dependency. At peak dosage around 2004–2005, John was prescribed over 1,100 mg of OxyContin daily alongside 13 other medications — far exceeding the typical 20–40 mg average — before the opioid epidemic was officially recognized. Dr. Lester Grinspoon's book "Marijuana, the Forbidden Medicine" was the turning point, leading John to recognize opioids as legal heroin and motivating his decision to pursue cannabis as a replacement. Transition off opioids took approximately 18 months of withdrawal, during which John developed his cannabis olive oil formula "Fusatima" — progressing from smoking to edibles to concentrated olive oil infusions. Fusatima is made with 3 liters of Costco olive oil and 1 lb of high-quality cannabis, slow-cooked at 180°F; one tablespoon yields ~300 mg combined THCA/THC, with a full dose of 4 tablespoons twice daily reaching ~2,400 mg. Lower heat during preparation preserves more THCA (non-psychoactive), while higher heat converts it to THC — allowing dosage customization depending on whether patients want psychoactive effects. THCA capsules made from raw, unheated cannabis are recommended for patients who want pain relief without the high, broadening the formula's accessibility. Post-surgery use at UCSF in June 2025 demonstrated Fusatima's clinical viability — John used no opioids after his sixth back surgery, self-administering the formula four days post-op with his surgeon's awareness. John's pain doctor Dr. Michael H. Moskowitz documented cannabis use in monthly medical records from 2005 to 2021, and those papers have since been used to educate other patients and gain acceptance from Medicare and Social Security. Advocacy efforts included writing Senator Dianne Feinstein starting in 2009, which John credits as contributing to OxyContin's removal from the market by 2011–2015, and writing Senator Obama in 2007 requesting rescheduling. Fentanyl's rise on the streets is directly linked to forced opioid withdrawal — patients lost prescriptions without a sanctioned alternative, and cannabis remains underutilized due to stigma even among marijuana advocates. Trump's executive order rescheduling cannabis to Schedule III is seen as a pivotal moment, though pharmaceutical companies including Jazz Pharmaceutical (105 patents), Pfizer (25), and Bristol-Myers Squibb (36) are positioned to commercialize it. Getting Fusatima into pharmacies — regardless of who manufactures it, including potentially a Sackler-backed company — is the stated goal, as insurance reimbursement only becomes possible once it reaches the pharmacy system. Core takeaway: growing your own cannabis is the most reliable path to access and affordability — patients who don't grow will struggle to maintain supply, and self-sufficiency is framed as the foundation of medical freedom. Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Networking gets a bad reputation. And honestly? It's earned it.For most people, the word conjures images of awkward small talk, business cards nobody keeps, and conversations that feel more like auditions than actual human connection. It feels transactional. It feels fake. And for a lot of women, especially, it feels like a game they were never taught how to play.But what if the problem isn't networking itself — it's the way we've been taught to think about it?On the 2B Bolder Podcast, host Mary Killelea sits down with Monique Kelley — professor, consultant, and author of Redefining Networking: How to Lead with Your Unique Value, an Amazon #1 Bestseller in Business Ethics — to completely reframe what networking is, what it isn't, and why getting it right might be the single most important career move you make.Monique is a two-time PRNEWS Top Women in PR award recipient, a founding member of CHIEF, and has been featured in FOX and Fast Company. She's built a career working with some of the biggest names in biopharma — Pfizer, Roche, Lilly, Johnson & Johnson — not by chasing opportunities, but by building meaningful relationships that opened doors long after the conversation ended. Today she teaches the only Career Readiness course at Boston University's College of Communication, shaping how the next generation of professionals show up, connect, and lead.This conversation covers it all — her career journey from a pre-med detour into communications and healthcare PR, the moment she stepped in to present to a major client when her boss was out and realized that relationships matter just as much as the deck, and the pivots that took her from agency life to in-house roles to fractional consulting and eventually the classroom.Mary and Monique dig into the real stuff:What most people fundamentally get wrong about networking — and why that misunderstanding is costing them real opportunitiesWhat "leading with your value" actually means in practice, not just as a concept but as a daily behaviorA clear, three-step framework for defining your unique value, choosing the right audience, and showing up consistently — on LinkedIn and beyondWhy your network isn't a list of contacts. It's a living system of people who understand what you bring and actively want to advocate for youHow to build a network from scratch when you feel like you have nothing to offer and nowhere to startWhy remote work and meeting overload are making organic connection harder than ever — and what to do about itThe truth about "I don't have time to network" (spoiler: it's a prioritization issue, not a time issue)What Monique is seeing right now across executives, students, and mid-career professionals — and the specific behaviors she notices in women who are actually building momentumWhat she teaches her Career Readiness students at BU that experienced professionals desperately need to hearAnd the one thing she wishes she had understood earlier about building a career that lastsWhether you're in the middle of a career transition, feeling stuck in a role that no longer fits, or just dreading the next industry event — this episode will completely shift how you think about connection, value, and what it actually means to build a career on your own terms.

Most UX professionals spend years trying to be good at everything. Eric Shumake, founder of HXR Labs, spent 20 years getting really good at one thing and it kept opening doors he didn't expect.Eric is a principal UX researcher and a well-known voice in healthcare UX. His career has taken him through companies like Pfizer, Johnson & Johnson, Novartis, Myriad Genetics, and AliveCor.He also teaches, including a popular course on Maven on breaking into healthcare UX, and has been exploring how AI can meaningfully (and responsibly) augment research without replacing the judgment that makes research trustworthy.In this episode, Eric and Sarah cover a lot of ground: how specializing almost always beats generalizing, what surprises people when they try to bring standard UX practices into clinical environments, why Eric thinks of every role as a gig, and what he'd prioritize if he were managing someone's job search like a product.Topics Discussed✅ Why specializing beats generalizing and how to niche down even when it feels risky✅ How transferable skills work in practice: why experience in one highly regulated industry (like finance) can open doors in another (like healthcare) ✅ The biggest blind spot people bring into healthcare UX✅ Why "recommendations are where insights go to die" and how to tie research to decisions and numbers so stakeholders actually act on it✅ Treating every role as a gig and why that mindset is more practical than it sounds in today's job market✅ Why posting consistently on LinkedIn is one of the highest-leverage things a UX professional can do in a job search right now✅ Where AI genuinely helps in UX research (desk research, competitive analysis, automating the time-consuming parts) and where to draw a hard line✅ What neurodivergence in the workplace looks like from the insideduring a job searchLinks & Resources

Avant de passer au programme n'oubliez pas d'activer la ligne direct de Tocsin !

It's been one year since the U.S. Centers for Disease Control and Prevention, in an unprecedented move, dismissed all the members of its Advisory Committee on Immunization Practices (ACIP), kicking off what would turn out to be a very concerning and busy year for infectious disease specialists.  We're going to recap this turbulent period – which includes a resurgence of measles, an unusually rough flu season, the emergence of a new COVID strain and outbreaks of hantavirus and Ebola – with Dr. William Schaffner, one of the country's most frequently quoted medical experts on infectious disease, vaccination, and public health. As a member of ACIP for decades, Dr. Schaffner brings unique insight into the dismantling of the committee and the distrust of vaccines that lies at the root of the changes. As he explains to Raise the Line host Lindsey Smith, while many vaccine critics are beyond reach, there are those he describes as vaccine hesitant that may be persuadable if the right approach is taken. “Beyond providing facts, we have to listen to them and respond to their concerns and make them feel comfortable. Information is fundamental, but behavior change only comes with a change in attitude.” Tune in for a wealth of wisdom and context that includes observations on: What's complicating containment of the Ebola outbreak; Challenges in public health communication in the current social media environment; What grade health authorities should get on their response to the hantavirus outbreak. Mentioned in this episode:Vanderbilt University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this interview I talked with the Senator from Wisconsin, Ron Johnson. We discussed his bombshell report called, Unmasked: How Biden Health Officials Purposely Turned a Blind Eye Toward COVID-19 Vaccine Safety Signals. In this report, Senator Johnson and his team reveals that many people within the FDA and HHS, among other governmental organizations, knew that the COVID-19 vaccines were linked to strokes and even death as early as 2021. Senator Johnson's team found conclusive evidence that the United States Government, the majority of American media companies, and the monopolistic Pharmaceutical Companies worked together to suppress the truth about the Vaccines and, in turn, killed thousands of innocent American citizens. For being one of the most significant reports in modern history, you would think that this story would be on the front page of every major news network and newspaper in America – you would be wrong. Senator Johnson sent his own Op-Ed regarding this report to The New York Times, The Wall Street Journal, USA Today, and many other publications and, to nobodies surprise, he was turned down for publication. We think this had something to do with the fact that many, if not all, of these news companies are sponsored by Pfizer or Moderna and would rather keep in good standing with their financiers than tell the American people the truth about what happened during the COVID-19 Pandemic. We, at The Paradox Press, are not beholden to the Medical Mafia and for that reason, we have the ability to tell the truth. I hope you enjoy. BUY DR MARY TALLEY BOWDEN'S BOOK Go subscribe to The Paradox Press now!Follow me on X: https://x.com/andyschmitt99

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers. The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in mergers and acquisitions. A recent analysis by PwC reports that M&A activity has reached over $65 billion in deal value during the first quarter of 2026, marking the strongest quarter since 2020. This uptick underscores a robust confidence within the industry, with companies strategically leveraging these mergers to bolster their pipelines and explore new therapeutic territories. Eli Lilly's acquisition of non-opioid pain drugmaker 4E is a case in point, as it reflects a broader industry shift towards precision medicine and non-opioid pain management solutions—a response to growing concerns over opioid addiction. On the regulatory front, notable developments include Colorado's drug import plan receiving FDA approval. This marks a bold step in curbing drug costs across the U.S., although implementation challenges remain due to complex logistical and regulatory landscapes. Meanwhile, Novo Nordisk is expanding its global manufacturing footprint with a new plant in the Czech Republic for diabetes and obesity drugs, alongside a $29 million investment to upgrade its Chinese facility. This expansion aligns with Novo's strategic preparation to seek Chinese regulatory approval for its Wegovy pill, potentially transforming the obesity treatment landscape. In a move that could reshape vaccine development, Moderna is advancing its mRNA-based influenza vaccine candidate through regulatory channels. The FDA's favorable reviews ahead of an advisory committee meeting highlight the growing acceptance of mRNA technology beyond COVID-19 vaccines. This technology holds promise for transforming vaccine development across various infectious diseases. Precision oncology continues to grapple with translating scientific discoveries into practical applications that genuinely improve patient outcomes. The ASCO 2026 conference emphasized this critical transition from discovery to implementation as essential for advancing precision medicine. Turning to gene therapy, UniQure is preparing for a significant milestone—submitting an accelerated Biologics License Application for its Huntington's disease therapy. This follows a reversal by the FDA, which now considers UniQure's Phase 1/2 trial data sufficient for submission. Should this therapy gain approval, it would be groundbreaking as the first genetic medicine for Huntington's disease, setting a precedent for future gene therapies targeting other genetic disorders. In another strategic partnership, Jazz Pharmaceuticals has teamed up with AbCellera to develop T-cell-engaging antibodies for oncology indications, illustrating the potential financial rewards associated with innovative cancer therapies. This collaboration could yield up to $820 million per program and highlights how partnerships are crucial in expediting drug development timelines. These stories reflect broader industry trends emphasizing innovation and strategic partnerships while navigating complex regulatory landscapes. The focus on precision medicine and advanced biologics continues to drive scientific advancements, with companies like Vedana Therapeutics targeting unmet needs in neurology through novel therapeutic approaches. Meanwhile, international collaboration is gaining traction in regulatory processes. The newly launched transatlantic liaison program between the FDA and MHRA aims to accelerate drug approvals and foster innovation across borders—an initiative that underscores the importance of collaborative frameworks. However, not all news is optimistic. Be Biopharma's decision to terminate its hemophilia B cell therapy trial highlights the challenges companies face in competitive therapeutic areas. Despite previous optimism, similar withdrawals by Pfizer and BioMarin indicate the necessity for robust clinical data and clear market differentiation strategies. Furthermore, Merck's recent agreement with Protillion Technologies marks an increased focus on integrating artificial intelligence into drug discovery processes—a trend promising accelerated timelines and improved trial success rates. As these developments unfold, it's evident that the pharmaceutical and biotech sectors are at an intersection where scientific innovation meets strategic business decisions. The potential approval of UniQure's gene therapy could catalyze further advancements in genetic medicine—while M&A activities suggest an industry poised for transformative growth. For stakeholders—from researchers to executives—the ability to adapt to these dynamic changes will be crucial in shaping the future of drug development and patient care. In conclusion, these stories collectively paint a picture of an industry evolving through scientific breakthroughs while adapting through strategic business decisions. As new technologies integrate into this space alongside regulatory advancements in gene therapy, this period of transformation holds promising implications for addressing unmet medical needs and enhancing therapeutic outcomes globally.Support the show

ThePrintPod: New drugs reach India 5-6 years late, approval time must be cut down to 12-18 months—Pfizer India head

In this episode of Data in Biotech, host Ross Katz sits down with Paul Finn, Chief Scientific Officer at Oxford Drug Design, for a conversation on what it actually takes to find a drug molecule that works not just on paper but also in the lab, in the cell, and, ultimately, in the clinic. Paul brings four decades of experience across what became GSK, Pfizer, and a series of Oxford-area spinouts and has shepherded a compound all the way to a marketed drug. That perspective gives him a particular kind of skepticism toward AI results that look too good to be true because he's done the work of checking whether they are. The conversation moves through synthesizability as a first-class constraint, why chemistry has proven so much harder for AI than biology, how 3D molecular representation gets closer to the physics that actually matters, and what rigorous multi-parameter optimization looks like when you're trying to kill cancer cells and drug-resistant bacteria at the same time. What you'll learn in this episode: >> Why synthesizability is chronically underestimated and why changing a single atom in a structure can take a molecule from trivially easy to make to practically impossible >> How Oxford Drug Design constrains the generative search to reaction schemes and purchasable building blocks, and why that chemical space is still so vast that novelty is not meaningfully sacrificed >> Why most generative AI models learn from a 2D string representation of a molecule; two steps removed from the 3D physics that govern how a drug actually binds to its target >> How Bayesian optimization over reagent space, rather than molecular space, allows an active learning loop to focus on the structural patterns associated with activity >> Why benchmarking complex models against simple ones is the discipline that exposes false correlations and why Paul and his co-authors were able to recover the Halicin result using methods decades older than deep learning >> What a pharma company should actually ask an AI drug discovery vendor before buying what they're selling Meet our guest: Paul Finn is Chief Scientific Officer at Oxford Drug Design, a computational drug discovery company with roots in Oxford's chemistry department. His career spans over 40 years of computational drug discovery, from early structure-activity modeling in the 1980s through to modern generative AI methods, with deep experience at what became GSK and Pfizer before moving into the Oxford spinout ecosystem. At Oxford Drug Design, Paul leads internal programs in oncology and antibacterial resistance, combining novel computational methods with a rigorous, synthesizability-first approach to multi-parameter optimization. Connect with Paul Finn on LinkedIn: https://uk.linkedin.com/in/paul-finn-2250616 About the host: Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/ Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. https://www.linkedin.com/company/corrdyn/

AUA2026: Focus on: Metastatic Urothelial Carcinoma CME Available: https://cme.auanet.org/URL/FOCUS264ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Select appropriate first-line therapies for patients with locally advanced or metastatic urothelial carcinoma during initial treatment planning, in accordance with updated NCCN guidelines. 2. Evaluate holistic management approaches, including treatment sequencing, therapy transitions, and long-term follow-up for patients with locally advanced or metastatic urothelial carcinoma throughout the course of disease. 3. Implement strategies to recognize, monitor, and mitigate treatment-related adverse events in patients receiving systemic therapy for locally advanced or metastatic urothelial carcinoma. 4. Integrate shared decision-making tools and communication strategies into clinical practice to ensure alignment of treatment choices with patient values and caregiver input. 5. Distinguish between treatment pathways for different stages of advanced bladder cancer, including variant histologies to ensure accurate staging and appropriate therapy selection based on the latest NCCN guidelines. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Merck & Co., Inc. Pfizer, Inc.

How do you rebuild a company's entire capability infrastructure — and fund the transformation through the savings it generates? Zaka Farhat is Global SVP for Talent, Learning, Organisation and Capability Development at GSK, where she leads the company's enterprise-wide skills, learning and capability agenda. In this episode, Zaka shares the full story of how GSK rebuilt its capability infrastructure in 18 months - retiring more than 20 legacy systems, building a single skills and learning ecosystem, and funding the transformation through the savings it generated. Join them as David and Zaka discuss:Why GSK's skills transformation began with a commercial question about capability and cost The five conditions for organisational readiness that had to be in place before any platform launched How GSK approached skills taxonomy, job architecture and inference, and what they had to redo along the way What personalised learning looks like at scale, and how skills data is now shaping workforce planning decisions What GSK chose to stop, and why decommissioning is the step most transformations skip How Zaka's team is measuring impact across three KPI layers This episode is sponsored by TechWolf. The world of work is being rewritten faster than HR systems can keep up. Skills age in months. Roles get redesigned quarter by quarter. CHROs have quietly become AI transformation leads, and the data they need to lead it doesn't exist in any HR system. That's why the world's most forward-looking enterprises such as HSBC, AMD, T-Mobile, GSK, ServiceNow, Pfizer, have built on TechWolf. As the data layer for the AI era of work, TechWolf gives enterprises the skills, they need to move faster and lead with confidence. Skills Intelligence, Work Intelligence, and Market Intelligence, in one layer. Visit techwolf.ai. Hosted on Acast. See acast.com/privacy for more information.

Send us Fan MailWe're living through the fastest technological acceleration in human history.Every week brings a new AI model, a new productivity tool, and a new prediction that everything is about to change forever.And yet somehow, most people feel less focused, less certain, and more overwhelmed than ever.In this episode of FUTUREPROOF., I sit down with Fredric Marshall, author of THRIVE: The Antidote to Future Shock, to explore a possibility we don't talk about enough:What if the biggest risk of AI isn't that it replaces humans?What if it's that it exhausts them?Fred has spent decades helping organizations like Apple, Pfizer, and Genentech navigate periods of intense change. His argument is that most organizations aren't suffering from a technology problem. They're suffering from an attention problem.We're surrounded by tools designed to save time, yet nobody seems to have any.We have more information than ever, yet many leaders feel less certain.And we keep calling it a productivity problem when it may actually be a human capacity problem.We discuss: Why "future shock" may be the defining leadership challenge of the AI era  How AI can reduce friction—or quietly create more of it  Why burnout is often a systems problem disguised as a personal one  The hidden cost of constant context switching  Why clarity may become more valuable than speed  How leaders can separate signal from noise  What it actually means to thrive during exponential change Because if every problem gets solved with another app, another dashboard, or another AI assistant...At some point, someone has to manage all those solutions.

Turn Setbacks Into Wins With Neutral Thinking   Success does not protect you from feeling stuck. In fact, for many high achievers, the pressure to keep performing can bury the deeper questions that actually matter. This conversation with Joshua Lifrak is about what happens when the old way of thinking stops working and you need a more honest framework for resilience, growth, and living with intention. Joshua knows this terrain from both sides. He grew up around financial scarcity, built a career in elite performance, and lived through bankruptcy before rebuilding. Along the way, he worked with top athletes and organizations, including the Chicago Cubs during their 2016 World Series run, and built a framework for performing under pressure that now serves business leaders as well.   In This Episode: How childhood scarcity shaped Joshua's early relationship with money Why bankruptcy became a turning point instead of an ending What elite athletes understand about mental preparation that most executives do not The power of neutral thinking in high-pressure moments Why knowledge without action changes nothing How to stop living by default and start living by design What "Mile Zero" means for your next chapter   Key Insights: The story you attach to a setback often creates more damage than the setback itself. Neutral thinking creates space for better decisions. Real performance is built before the pressure moment arrives. Growth comes from repetition, not occasional inspiration. The past only controls the future if you keep giving it that power.   Money Learnings from Joshua: He grew up with a scarcity-based relationship to money and remembers what it felt like when finances were tight at home. School did not teach him much about money, and he says he did not truly begin to understand how money could work for you until later in life. He credits his wife, Karen, with helping shape a more thoughtful financial approach through long-term planning, investing, and thinking differently about how to use money to create freedom and better choices.   Why This Conversation Matters: It speaks directly to entrepreneurs and high achievers who know what pressure feels like. Success does not eliminate setbacks, self-doubt, or emotional overreaction. In many cases, it raises the stakes. Joshua brings a rare perspective because he connects personal financial struggle, elite athletic performance, and business leadership into one practical framework. For anyone building a company, leading a team, or trying to grow through a difficult season, this episode is a reminder that better results often begin with better thinking. This is what makes the conversation so relevant for entrepreneurs and high achievers. Success does not remove pressure. It often amplifies it. And when pressure rises, the real question is whether you will react emotionally or respond with intention. Joshua's concept of neutral thinking offers a grounded way forward.   About Joshua Lifrak: Joshua Lifrak, M.S., author of WIN TODAY, is Director of Performance and Coaching at Limitless Minds, a mental performance consultancy, delivering keynotes and advising individuals, small businesses, and top multinationals including McDonalds, Novartis, Pfizer, KPMG, and Amazon. He started his career as a mental conditioning consultant with IMG Academy, working with MLB players, NBA and NFL draft picks, the US Soccer U-17 Men's National Team and many elite college programs. He then joined the Chicago Cubs as director of their mental skills program. His work there culminated in the Cubs' 2016 World Series victory. After his stint with the Cubs, he went on to be the Major League Mental Skills Coach for the New York Mets. Lifrak, who has a Master's Degree in Exercise Science with a specialization in Sports Psychology from Ithaca College, lives in Sarasota, Florida.   Links: LinkedIn: https://www.linkedin.com/in/joshua-lifrak-59ab5442/   Facebook: https://www.facebook.com/jlifrak/   Instagram: https://www.instagram.com/joshualifrak/  And here's a link to an advance copy of the book:    https://app.box.com/s/qgi7q7093iaqmh0twvhlyx877y8xs9t9    Watch the full episode on YouTube: https://www.youtube.com/@richersoul Richer Soul Life Beyond Money. You got rich, now what? Let's talk about your journey to purposeful, intentional, amazing life. Where are you going to go and how are you going to get there? Let's figure that out together. At the core is the financial well being to be able to do what you want, when you want, how you want. It's about personal freedom! Thanks for listening! Show Sponsor: http://profitcomesfirst.com/ Schedule your free no obligation call: https://bookme.name/rockyl/lite/intro appointment 15 minutes If you like the show please leave a review on iTunes: http://bit.do/richersoul https://www.facebook.com/richersoul http://richersoul.com/ rocky@richersoul.com Some music provided by Junan from Junan Podcast Any financial advice is for educational purposes only and you should consult with an expert for your specific needs.

CNBC reports that health care investment bankers see a selective biotech IPO window reopening while big pharma M&A continues to lead exits. Recent deals include Pfizer buying Seagen for $43 billion, Bristol Myers Squibb acquiring Karuna Therapeutics for about $14 billion, Merck purchasing Prometheus Biosciences for $10.8 billion, and Bristol Myers Squibb acquiring RayzeBio for $4.1 billion. IPO activity has included CG Oncology raising about $380 million in January 2024, Kyverna Therapeutics raising roughly $319 million in February 2024, and Tempus AI raising about $410 million in June 2024. Bankers say offerings that price well feature crossover anchors, late-stage data, and twelve to eighteen month catalysts. Strategic buyers maintain pricing power due to patent cliffs and policy pressure, with oncology and immunology assets favored. Founders are advised to prepare for dual-track processes, manage burn, and build a crossover base before filing an S-1.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

Informed Dissent with Dr. Jeff Barke – Take the recent respiratory syncytial virus vaccine for pregnant women. The manufacturer's label notes postmarketing reports of increased preterm birth and of neurologic events such as Guillain-Barré syndrome. The label lists residual host cell proteins from Chinese hamster ovary cells and polysorbate 80 among components...

Informed Dissent with Dr. Jeff Barke – Take the recent respiratory syncytial virus vaccine for pregnant women. The manufacturer's label notes postmarketing reports of increased preterm birth and of neurologic events such as Guillain-Barré syndrome. The label lists residual host cell proteins from Chinese hamster ovary cells and polysorbate 80 among components...

The best practices aren't built on systems and numbers — they're built on something that's easy to forget.In this episode, Bree Groff breaks down why people are the backbone of a practice and how leaders can bring out their team's best. Working with teams at Google, Microsoft, and Pfizer, she's developed simple exercises and team practices that  drive performance and bring fun to any size practice.Topics discussed:The "performative exhaustion" trapWhat people need more than a paycheckThe most underrated leadership roleHow to make work fun and show that you careTwo simple tools that help teams connectShould you be friends with the people you lead?This episode was produced by Podcast Boutique https://www.podcastboutique.comCheck out the Growth Program Here Join our Newest and Best Coaching Program, Click Here for More InformationTake Control of Your Practice and Your LifeWe help dentists take more time off while making more money through systematization, team empowerment, and creating leadership teams.Ready to build a practice that works for you? Visit www.DentalPracticeHeroes.com to learn more.

What if the gap between what you want and what you get comes down to how you communicate? Today on The Next Big Idea Daily, we're exploring the art and science of human persuasion. MIT and Harvard Law negotiation experts John Richardson and Attia Qureshi bring us practical advice from their new book ⁠Never Settle: Persuasion and Negotiation Skills to Get What You Want⁠. Then, Sally Susman — Chief Corporate Affairs Officer at Pfizer and one of Forbes' World's Most Influential CMOs — shares strategies from her 2023 book Breaking Through: Communicating to Open Minds, Move Hearts, and Change the World. Then, Whether you're trying to lead, persuade, or just get a better deal, these two have you covered.

Bret Weinstein speaks with attorney, Bobbie Anne Cox on the subject of election laws, voter fraud, and the political landscape in blue states. But first they honor the legacy of their friend, Warner Mendenhall, in discussing the Brooke Jackson case and fraud in Pfizer Trials.Find Bobbie Anne Cox on X at https://x.com/Attorney_Cox and her Substack at https://attorneycox.substack.com. *****Sponsors:Xlear: Xylitol nasal spray that acts as prophylaxis against respiratory illnesses by reducing the stickiness of bacteria and viruses. Find Xlear online, or at your local pharmacy, grocery store, or natural products store.Vanman: Go to https://vanman.shop/darkhorse26 and use code DARKHORSE26 for 15%  off your first order.SaunaSpace: Dark Horse listeners get an exclusive 10% off sitewide at http://sauna.space/darkhorse - now through June 21, every sauna purchase includes a FREE PureLayer bundle featuring an organic bamboo mat cover and three stool covers.*****Join DarkHorse on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comCheck out the DHP store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://www.darkhorsestore.orgTheme Music: Thank you to Martin Molin of Wintergatan for providing us the rights to use their excellent music.*****Mentioned in this Episode:Brownstone Institute https://brownstone.org/ In Memory of Warner Mendenhall https://imahealth.org/in-memory-of-warner-mendenhall Brook Jackson's fight against Pfizer https://www.covidlawcast.com/p/brook-jacksons-fight-against-pfizerUNITED STATES OF AMERICAex rel. BROOK JACKSON,Plaintiff,vs.VENTAVIA RESEARCH GROUP, LLC,et al.Defendants https://www.documentcloud.org/documents/24362542-2023-12-19-jackson-opp2mtd-final-as-filed/H.R.5546 - National Childhood Vaccine Injury Act of 1986 https://www.congress.gov/bill/99th-congress/house-bill/5546 National Vaccine Injury Compensation Program https://www.hrsa.gov/vaccine-compensation HHS, CDC Announce New ACIP Members https://www.hhs.gov/press-room/hhs-cdc-announce-new-acip-members-sept-2025.html CPPAC 2026: Bobbie Anne Cox https://www.youtube.com/watch?v=7p3YItoDArs When Judges Go Rogue https://attorneycox.substack.com/p/when-judges-go-rogue When Judges Go Rogue - Bobbie Anne Flower Cox - The Brownstone Show, Episode 15 https://www.youtube.com/watch?v=IVZTHV-bZN8SAVE Act https://www.congress.gov/bill/119th-congress/house-bill/22Support the show

This week, we take a quick trip to Stockholm, Sweden, where ESTRO (European Society for Radiotherapy and Oncology) took place several weeks ago. A/Prof Steven David digs deep into the latest updates in the breast cancer radiation space, including hyperfractionation of treatment, the utilisation of AI for radiation planning (Archery Trial), and the DBCG RT Natural Trial, which examined whether omitting partial breast irradiation (PBI) after breast-conserving surgery was safe in those over 60 (spoiler: you should still give PBI).For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (6/13/26). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v7928qe","div":"rumble_v7928qe"}); Source Links (In Chronological Order): Hungary Becomes First European Nation To Ban Rothschild Banks US State Department Admits Plans To Meddle In Hungary's Democracy The Pro-War Network Behind Hungary's New Foreign Minister: Anita Orbán's Deep U.S. Ties - The Last American Vagabond New Tab (21) Reclaim The Net on X: "The White House will reportedly block states from making their own AI laws and, in exchange, it's indirectly backing a national age verification push. So to post online you'd upload a government ID or do a face scan through the Kids Online Safety Act and the NO FAKES Act..." / X Trump Moves to Deeply Censor the Entire Internet New Tab (21) Rapid Response 47 on X: "Q: There's a crazy socialist running for mayor of Washington, D.C. What if she wins? @POTUS: "I wouldn't like it — and maybe we take back Washington, run it on the federal basis. We won't put up with it. We're not going to lose our businesses." https://t.co/XDG1977D2W" / X (21) 7News DC on X: "President Donald Trump on Thursday threatened to "take back Washington" if Janeese Lewis George won the D.C. Mayoral race. Lewis George, a democratic socialist who is leading the race, told 7News in a statement that the threat is an "attack on democracy itself." #wjla https://t.co/u62Jj3XF1B" / X STUDY: National Guard deployed to DC had no effect on violent crime – NBC4 Washington District of Columbia | Violent Crime in D.C. Hits 30 Year Low | United States Department of Justice Safe & Clean - The City of Memphis Memphis Crime Drops to Historic 25-Year Low Across Major Categories - Memphis Police Department REVEALED: Deputy Director of ICE was sent by the ADL for training with the Israeli military - JVP New Tab New NDAA (Further) Integrates US and Israeli Militaries & The Ongoing Axios/Iran War Deception Israeli Firm BlackCore Suspected of Meddling in NYC, Scotland Elections, French Official Says - National Security & Cyber Israeli Company Caught Manipulating At Least 33 Elections, Red Cross Caught & Is There More To Ohio? The Israeli Election Interference and Psychological Operation Industrial Complex (21) GenXGirl on X: "What a rare find thanks to @ifamericansknew In response to a Zionist claiming only Muslims commit terrorism, CNN reports on air, between 1980-1985, there were 18 terrorist attacks committed by Jews, 15 of them were by members of the Jewish Defense League. Today, Bari Weiss is https://t.co/0g9vdoPJHe" / X Trump's DOJ approves Paramount-Warner Bros. merger, as potential state lawsuits loom | CNN Business (21) Brian Tashman on X: "Very sad. Israelis ran a fake charity purportedly to help children in Gaza that served as “a honeypot: a decoy built to attract people who wanted to help – in this case, by aiding Palestinians – and to take donors' money, their personal data or both.” https://t.co/EwOu4sRC19" / X Revealed: An Anti-left Influence Op in France Leads to Tel Aviv - National Security & Cyber AI-Generated Deepfake Ads Target Kentucky GOP Candidates in Defamatory Political Attacks - OECD.AI Massie race breaks spending record as pro-Israel groups target Trump critic | US Midterm Elections 2026 News | Al Jazeera The Fake Gaza Charity Linked to the Anti-left Disinformation Campaign in France - National Security & Cyber (21) Ambassador Mike Huckabee on X: "This is why Jews say “Never again.”" / X Home | AI or Not New Tab (21) Thomas Massie on X: "Republicans are in charge because we promised: to Make America Healthy Again. to start No New Wars, to put people above corporations, to put America above foreign countries, to release the Epstein files, to not spy on citizens, to eliminate fraud, what the hell happened?!" / X (21) Agorist Nexus (Brandon) on X: "https://t.co/WiZrKPNMi1" / X (21) Jamison Daniel on X: "MAGA-influencer Riley Gaines being told/paid by Patriot Mobile handlers what her "sincerely held" beliefs are in leaked video. Mar-A-Lago Face is a phenomenon that needs to be studied academically. https://t.co/IvdBNAdzqc" / X (21) Clint Russell on X: "Elon...OUT MTG...OUT Tulsi...OUT Massie...OUT RFK Jr...soon to be OUT The entire coalition was a lie. An elaborate mirage to skinsuit neocons as MAGA. If you haven't figured out that you got played by now you simply never will." / X (21) The Last American Vagabond on X: "Seriously man? @LibertyLockPod https://t.co/V6yah9IDIv" / X New Tab (21) Mary Talley Bowden MD on X: "Everyone thinks Kennedy is secretly on our side. Proof he's not. ⬇️" / X (21) The Last American Vagabond on X: "We told you this was still happening from the very beginning of this administration. They are also leaning into the self-amplifying shots: https://t.co/u0DUYNfwVb" / X SAM.gov SAM.gov Trump Admin Leans Into Self-Amplifying mRNA (SamRNA) Under Guise Of Ending mRNA & RNA In Food (20+) Video | Facebook BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) Bravecto Quantum: Insight from a dermatologist - AAHA Is Bravecto Safe for Pregnant Dogs? A Careful Look at Fluralaner in Br – HERO Veterinary FDA approves first long-acting flea and tick treatment for dogs | FDA SPC_2808659.PDF New Study Shows Common Insecticide Is Killing Bee Sperm Obligatory Pesticide Spraying In NYC, GM Mosquitoes & Flying Vaccinators - Are They All Connected? (21) Secretary Kennedy on X: "Today, I signed a targeted PREP Act declaration to support the development and deployment of medical countermeasures related to Andes virus, which can cause the deadly respiratory illness Hantavirus Pulmonary Syndrome. This action helps remove barriers to research and response" / X Stargate: Trump Partners with Technocrats to Promote mRNA Injections, AI, and Transhumanism The Pentagon Quietly Delayed PFAS Cleanup Across Nearly 200 Military Sites - NOTUS — News of the United States Causes of Infertility: New Study Points to PFAS, or 'Forever Chemicals' Federal Court Overturns Historic Fluoride Ruling as Trump Admin Fights to Keep Fluoride in the Water New Tab (21) Andrew Kolvet on X: "Fauci lied. People died. This is why Fauci was given a "full and unconditional" pardon by Biden's autopen. An absolute travesty." / X Israeli Citizen Charged In The Las Vegas "Biolab" Case As Fort Detrick Investigates Sabotage Israeli Biolab Update, 13 US Bases "All But Uninhabitable" After Strikes & Trump's Faux Negotiation (21) Kirill Dmitriev on X: "Biden's 40 biolabs in Ukraine finally disclosed by the US." / X FACT SHEET: The Department of Defense's Cooperative Threat Reduction Program - Biological Threat Reduction Program Activities in Ukraine Feds lift gain-of-function research pause, offer guidance | CIDRAP Understanding the Risk of Bat Coronavirus Emergence - The Intercept RePORT ⟩ RePORTER Human-animal interactions and bat coronavirus spillover potential among rural residents in Southern China - PMC Baric CV 2001 RePORT ⟩ RePORTER RePORT ⟩ RePORTER (21)

In this explosive Patriots With Grit interview, Special Guest Mike Dillon of AirWaterHealing.com breaks down the growing concerns surrounding RFK Jr., Big Pharma influence, the Pfizer meeting fallout, and why many Americans feel the MAHA movement is being derailed. From broken promises and political pressure to grassroots health freedom and the future of America's food and medical systems — this is the conversation they don't want you to hear.https://AirWaterHealing.com. Promo Code GritNOTE: This information is for educational and investigative purposes.-------------------------Check out all of our vendors at: https://patriotswithgrit.com/patriot-partners/SPONSORS FOR THIS VIDEOGold, Silver and Precious Metalshttps://NobleGoldInvestments.com/GRIT❤️ Cardio Miracle – One Drink. Endless Benefits.Feel steady energy, sharper clarity, and stronger resilience every day.Own your freedom in health & experience the full power your body was designed for.

A growing number of biotechs are defying the perception that you need the might of big pharma to launch a new drug. But there's always the prospect of an offer that simply can't be refused. Three leaders who recently sold companies – Whit Bernard (Metsera), Mike MacLean (Avidity), and Gregory Kunst (Aurion) – shared their experiences, and their views on M&A trends in the sector, at RBC's recent Global Healthcare Conference.Key points:Metsera managed to stay focused on business through a high-stakes bidding war.A strong sense of its own value helped Avidity to its Novartis buyout.In a tough capital-raising landscape, biotechs need to be open to partnerships with bigger firms.While the patent cliff is spurring pharma deals, corporates have a variety of M&A objectives.A series of successful drug launches by small innovators may signal the end of investors' ‘short the launch' strategy.Introductions [00:07]Host Joe Colletti introduces highlights from the M&A panel at RBC's Global Healthcare Conference, featuring Brian Abrahams and colleagues posing questions to Whit Bernard (Metsera), Mike MacLean (Avidity), and Gregory Kunst (Aurion).Biotech histories [01:01]Each of the execs outlines the background to their former companies and the therapies they developed.Avidity's experiences [05:43]Mike MacLean discusses the experience of negotiating with Novartis, through multiple bids and a decision by Avidity to pursue its own capital raise before the eventual acquisition.Metsera's experiences [09:32]Whit Bernard recalls how Metsera responded to becoming the subject of a competitive deal between Pfizer and Novo Nordisk. Capital raising methods [11:53]Gregory Kunst suggests CEOs should be open to raising capital through strategic partnerships as well as traditional institutional funding.What pharmas want [14:07]Big pharma is broadly incentivized by the patent cliff, but biotechs need to understand the varying objectives of different companies.Short the launch strategy [23:42]Investors are taking a different view of start-ups' capabilities as more small and mid-sized biotechs commercialize their own innovations.

"Until immunomodulators, patients [with myeloma] did not have a great overall survival rate. But when we introduced lenalidomide, we started seeing our patients have life expectancies between five and seven years—which was unheard of prior to these immunomodulators going forward. I think it's promising and allows patients to have quality of life versus therapy of life," ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about immunomodulators. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 12, 2027. Daniel Verina is on the speakers' bureau for Johnson & Johnson, GlaxoSmithKline, and Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome:  Learners will report an increase in knowledge about the use of immunomodulators to treat cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses Episode 386: Interprofessional Navigation and the Oral Anticancer Medication Care Compass Episode 290: Cancer Symptom Management Basics: Peripheral Neuropathy ONS Voice articles: Maintain Oral Adherence With ONS Guidelines™ Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Sexual Considerations for Patients With Cancer Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum articles: Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS book: Multiple Myeloma: A Textbook for Nurses (third edition) ONS Symptom Intervention resource: Peripheral Neuropathy Risk Evaluation and Mitigation Strategies (REMS) Lenalidomide Pomalidomide Thalidomide International Myeloma Foundation: Using Immune Therapy to Fight Multiple Myeloma International Myeloma Society Multiple Myeloma Research Foundation: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We definitely want the diagnosis of multiple myeloma before initiating these drugs. We're going to look at serum protein electrophoresis. We want to make sure that we know the patient has serum free light chains and myeloma proteins to really confirm their disease. Plus, a bone marrow biopsy." TS 7:21 "Each immunomodulator has slightly different side effects. Thalidomide's biggest side effects are constipation, weakness, fatigue, somnolence, peripheral neuropathy, mood swings, hand tremors, and depression. With each generation, less of the side effects actually occurred. Most of lenalidomide's side effects, not discounting the deep vein thrombosis, are pancytopenia—the neutropenia, the anemia, and the thrombocytopenia. [The side effects] are very similar in pomalidomide." TS 15:40 "The REMS program is critical for oral immunomodulator therapies—thalidomide, pomalidomide, and lenalidomide. It was developed due to the risk of developing embryofetal toxicities. ... It is mandatory testing and counseling, so all females of reproductive potential must have two negative pregnancy tests prior to starting the therapy and then monthly pregnancy tests while on the therapy alone. Again, they must use two forms of effective contraceptives or abstain from heterosexual sex four weeks prior, during, and after. And the same thing for men. I focus on that because males may say, 'I have a vasectomy.' These therapies tend to bind to the semen. So, males must still use a latex or synthetic condom during any sexual contact with a female of reproductive potential, even if they did have a vasectomy." TS 18:31 "The capsule itself cannot be chewed, crushed, or opened. I bring that up because as healthcare professionals, we have educated our patients. If it's difficult to swallow capsules or tablets, we've always said to them, 'Oh, don't worry, just crush it into applesauce or open it up and sprinkle it on your mashed potatoes.' But because of this embryofetal toxicity, I advise my patients not to open the capsule. If they can't swallow it for any reason, they have a sore throat or they're just unable to, then [we tell them] to hold the therapy and then call us." TS 22:49 "We spoke about three generations already, but there's actually a fourth generation [of immunomodulators]. They're called cereblon E3 ligase modulators(CELMoDs). They're still in clinical trials but really showing promise in the therapy of myeloma. They're showing very good affinity to cereblons, just like the immunomodulators do. I think, in all cancer therapies, as newer generations come out or newer therapies move forward, some of the older generations might move aside, but they get integrated later on. So I don't think [immunomodulators] will disappear totally, but they will probably be modified." TS 36:39

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical portfolio strategy.  This episode has accompanying slides that can be found on YouTube https://youtu.be/DKdy_MShWBA They tackle the growing view that the pharmaceutical industry doesn't just have a science problem; it has an execution problem. Alex breaks down how human biases, such as confirmation bias and champion bias, can derail clinical development and lead to poor portfolio choices. They emphasize that stopping a failing project early is just as critical to an organization's overall success as advancing a good one.  The episode explores successful decision-making frameworks from top-performing companies, analyzing how AstraZeneca's 5Rs framework reversed late-stage failures and examining structured matrices such as Roche's RAVE, Amgen's RAVE, and Pfizer's DICE. Alex also highlights Eli Lilly's highly successful Chorus unit and their use of AI to drive objective resource allocation. Tune in to hear why relying solely on standard Probability of Technical Success (PTS) models or Risk-Adjusted NPV is flawed, how operational issues drive numerous Phase 3 failures, and the incremental but powerful role machine learning will play in the next generation of drug development.

Der Börsengang von SpaceX ist kein normales IPO, sondern ein Stresstest für Anleger, ETFs und Indexanbieter. Deshalb dominiert er den ersten Teil unserer Q&A-Reihe: Tobias Kramer beantwortet eure Fragen zu SpaceX, Starlink, American Tower, DAX und FAZ-Index, Gesundheitsaktien und Depot-Transparenz – nüchtern, mit Zahlen, ohne Hype. SpaceX kommt zu 135 bis 162 Dollar je Aktie an die Börse, das entspricht einer Bewertung von 1,8 bis 2,1 Billionen US-Dollar. Neue Class-A-Aktionäre halten danach zusammen gerade einmal 11,5 Prozent der Stimmrechte, während Elon Musk über seine Class-B-Aktien mit zehnfachem Stimmrecht rund 85 Prozent der Stimmen kontrolliert. Tobias rechnet einen bewusst optimistischen Bull Case durch (400 Mrd. Umsatz und 30 Prozent Nettomarge bis 2033) – und landet selbst dann bei einer unbequemen Antwort auf die Frage: Wie viel Zukunft ist hier schon bezahlt? Die Themen im Überblick: ▪️ Starlink Mobile als Angriff auf Deutsche Telekom, T-Mobile US und den globalen Mobilfunkmarkt – Chance, Schwachstelle und Frequenz-Politik ▪️ Nasdaq 100 vs. S&P 500: Warum die Fast-Track-Aufnahme von SpaceX Kritik verdient – und der S&P 500 mit seinen Regeln überzeugt ▪️ American Tower: Hat der Funkturm-REIT gegen Starlink noch eine Zukunft? ▪️ SpaceX shorten? Warum Tobias dringend davon abrät – Stichwort Lock-up-Fristen und Optionsprämien ▪️ DAX oder FAZ-Index: Welcher deutsche Index gehört ins Depot? ▪️ Gesundheitsaktien (Abbott, Medtronic, Pfizer, Boston Scientific): Übersehener Sektor oder Value-Falle? ▪️ Depot-Einblick: Der Link zur Google-Sheet-Übersicht steht in den Timestamps Unterm Strich eine klare Absage an Bewertungsromantik: Große Visionen reichen nicht, wenn Anleger heute schon den Gewinn von übermorgen bezahlen. Schreibt in die Kommentare, wie ihr den SpaceX-Case rechnet: 2 Billionen gerechtfertigt, 60 Prozent Rückschlagpotenzial – oder seht ihr den Weg zu 10 Billionen? Und wenn ihr solche Q&A-Folgen wollt: Abonniert den Kanal und meldet euch für unseren Mail-Verteiler auf echtgeld.tv an – dort laufen Umfragen, Fragerunden und Verlosungen. Teil 2 mit den weiteren Fragen (u. a. Marvell Technology und LVMH) folgt in der nächsten Sendung.

"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South.  On this episode of Raise the Line from Elsevier, Bussey provides illuminating  examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most.   Mentioned in this episode:  Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

This episode covers: Cardiology This Week: A concise summary of recent studies Transcatheter treatment of tricuspid regurgitation Carcinoid heart disease Milestones: MADIT-II Trial Host: Wilfried Mullens Guests: Stephan Baldus, Heidi Connolly and Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2560 Want to watch that extended interview on transcatheter treatment of tricuspid regurgitation, go to: https://esc365.escardio.org/event/2560?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Heidi Connolly, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Wilfried Mullens Guest: Stephan Baldus Want to watch that extended interview, go to: https://esc365.escardio.org/event/2560?resource=interview Want to watch that entire episode? Go to: https://esc365.escardio.org/event/2560   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The pharmaceutical and biotech industries are undergoing significant transformations, driven by scientific advancements, regulatory changes, and strategic investments. These developments are shaping the landscape of drug development and patient care in profound ways. In recent news, Pfizer's CEO, Albert Bourla, is reconsidering investments in Germany due to proposed healthcare reforms. These reforms have sparked concerns about their potential impact on the pharmaceutical industry. This situation highlights the intricate balance between regulatory frameworks and corporate strategies, illustrating how policy changes can influence investment decisions and operational strategies within the pharma sector. The tension between regulatory environments and corporate interests is a recurring theme that continues to shape strategic directions within the industry. Meanwhile, heightened scrutiny over biotechnology operations is evident with Wuxi AppTec's inclusion on the Pentagon's blacklist under the Biosecure Act. This move reflects growing concerns about biosecurity and the necessity for stringent oversight in handling sensitive biotechnological advancements. Such actions underscore a global focus on safeguarding national security while fostering scientific innovation. Teva Pharmaceuticals is navigating restructuring efforts by laying off 250 employees at its Active Pharmaceutical Ingredients unit as it seeks a new owner. This restructuring underscores the challenges companies face in maintaining operational efficiency amid ownership transitions. These challenges are emblematic of broader industry dynamics where companies strive to adapt to changing market conditions while ensuring stability and growth. On the scientific front, Novo Nordisk's cagrisema and Eli Lilly's retatrutide are emerging as next-generation incretin therapies. Although early comparisons have been made, Novo Nordisk's chief scientific officer suggests it is premature to declare a definitive leader. This competition reflects the dynamic nature of drug development as companies strive to innovate and improve treatment options continuously. Additionally, Sonothera's successful $125 million Series B funding round for its bubble-based genetic delivery system highlights the biotech industry's momentum fueled by mergers and acquisitions (M&A) and partnerships. Such technologies promise to advance genetic therapies by enhancing delivery mechanisms, potentially transforming treatment paradigms for various genetic disorders. AbbVie's Skyrizi narrowly surpassing Johnson & Johnson's Tremfya in May drug ad spending underscores the competitive nature of pharmaceutical marketing. Despite a general slump in advertising expenditures among leading drugs, strategic marketing remains crucial for maintaining brand presence and market share. Increased M&A activity and partnerships are further bolstering the industry's growth trajectory. The resurgence of Initial Public Offerings (IPOs) and venture capital funding is fostering innovation and expansion within the sector, providing fuel for continued advancement in biotech. On the regulatory front, Johnson & Johnson's Darzalex received a new endorsement from NICE after a prior reversal. Such regulatory updates emphasize the evolving nature of drug approvals and market access strategies essential for pharmaceutical companies' success. Novartis' second deal with Orionis Biosciences worth up to $1.4 billion exemplifies strategic investments aimed at expanding research capabilities and addressing unmet medical needs through molecular glue technologies targeting challenging therapeutic areas. Conversely, Sanofi's decision to halt a Phase 3 autoimmune trial due to insufficient efficacy highlights the inherent risks in drug development pipelines. These setbacks emphasize the importance of robust clinical trial designs and adaptability in R&D strategies. Emerging insights into GLP-1 drugs like Novo Nordisk's semaglutide reveal potential antidepressant effects linked to gut microbiota modulation. These findings open new avenues for exploring psychiatric applications of metabolic drugs, although conflicting data necessitates further investigation. Overall, these developments illustrate a complex interplay of scientific innovation, regulatory dynamics, and strategic corporate actions driving the future of pharmaceuticals and biotechnology. The sector continues to navigate challenges while capitalizing on opportunities to enhance patient care through advanced therapeutic solutions. The industry's trajectory promises transformative impacts on patient care through novel therapies designed not only to treat symptoms but also address root causes via innovative science-driven solutions. As these advancements unfold, they herald a new era of targeted, effective treatments that hold promise for improving patient outcomes across diverse medical landscapes.Support the show

How do you market the biggest sporting event on Earth? For Bettina Garibaldi, Chief Marketing & Communications Officer for the FIFA World Cup 2026 New York/New Jersey Host Committee, the answer goes far beyond advertising. It's about uniting communities, coordinating thousands of stakeholders, and creating experiences that millions of people will remember for the rest of their lives. After more than two decades leading global campaigns for brands like P&G, Unilever, Pfizer, and Gillette, Bettina stepped into what she calls a once-in-a-lifetime opportunity: helping bring the FIFA World Cup to North America. She shares how marketing sits at the center of everything, from fan engagement and city storytelling to transportation, public safety, tourism, and local business participation. She also reveals why the best marketing often happens behind the scenes, long before fans ever arrive at the stadium. Whether you're a Marketer, sports fan, business leader, this episode is for YOU.  Wrike brings structure, visibility, and accountability to work, so companies can make better business decisions, improve efficiency, and reduce risk. Learn more at https://wrike.com/tmm Follow Bettina: LinkedIn: https://www.linkedin.com/in/bettina-garibaldi/ Follow Daniel: YouTube: https://www.youtube.com/@themarketingmillennials/featured Twitter: https://www.twitter.com/Dmurr68 LinkedIn: https://www.linkedin.com/in/daniel-murray-marketing Sign up for The Marketing Millennials newsletter: www.workweek.com/brand/the-marketing-millennialsDaniel is a Workweek friend, working to produce amazing podcasts. To find out more, visit: www.workweek.com

In this final episode of the ICH Quality series, we walk through the most important concepts in ICH Q14 and how they fit into the broader ICH quality framework.Rather than reviewing the guideline section by section, this episode focuses on the ideas that are most useful in practice: Why does ICH Q14 start with the Analytical Target Profile (ATP)? How is it different from ICH Q2? How do you develop analytical procedures using a science- and risk-based approach? And what does all of this have to do with ICH Q12 and lifecycle management?One quick note: at the time of recording, ICH Q14 remains under public comment, so some details may evolve before the final version is adopted.Chapters00:00 – Intro and ICH Q14 vs. Q201:08 – The Analytical Target Profile (ATP)04:16 – The Analytical Procedure Lifecycle05:32 – Risk-Based Development and Enhanced Approaches06:20 – Where ICH Q2 Fits: Validation08:04 – Connecting Q14 to ICH Q12 and Lifecycle Management09:22 – Closing the ICH Quality SeriesIn this episode, we cover:• Why ICH Q14 exists• The difference between ICH Q14 and ICH Q2• What an Analytical Target Profile (ATP) is• ATP examples and performance criteria• Technology selection and fit-for-purpose methods• The analytical procedure lifecycle• Risk assessments and enhanced development approaches• Multivariate experiments and DOE concepts• Analytical procedure control strategies• Validation and the role of ICH Q2• Lifecycle management of analytical procedures• The connection between ICH Q14 and ICH Q12• Why understanding matters more than simply checking a boxIf you've followed along through the ICH Quality series, one of the themes that keeps showing up is that quality isn't something you test into products at the end. Whether we're talking about Q8, Q9, Q10, Q12, or now Q14, the emphasis continues to shift toward building knowledge, understanding risk, and using that understanding throughout the lifecycle.Subhi Saadeh is the Founder and Principal at Let's Combinate, where he helps teams develop and control drug-device combination products by aligning quality systems, development, and regulatory expectations across drug and device domains. He is a consultant, auditor, trainer, speaker, and host of the Let's Combinate podcast, with experience across companies including Pfizer, Gilead, and Baxter supporting vaccines, biologics, generics, and combination products.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800SummaryThis CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.Learning ObjectivesEvaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Faculty and Moderator Aditya Bardia, MDProgram Director, Breast Medical Oncology, UCLAProfessor of Medicine, UCLALos Angeles, CADr. Bardia has disclosed the following financial relationships:Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeAdvisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeContracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, PfizerStock options: Vyome (immuno-inflammatory and rare diseases)All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.Maura Di Nicola, MDAssistant Professor of OphthalmologyBascom Palmer Eye InstituteMedical Director of Imaging and EchographyBascom Palmer Eye InstituteMiami, FLDr. Di Nicola has disclosed the following financial relationships:Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)Advisor/Advisory Board: AbbVie (ophthalmology)Research Grant: Castle Biosciences (ocular oncology)Please review additional planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

How do the world's most forward-thinking organisations use skills intelligence, market intelligence and work intelligence together to stay ahead? In this episode of the Digital HR Leaders podcast, host David Green is joined by Mik Wornoo, co-founder and President of US at TechWolf, to explore how organisations are using three signals together to build a strategic workforce planning strategy that can keep pace with AI, and what that looks like in practice. In this conversation, David and Mik discuss: What skills intelligence, work intelligence and market intelligence each bring to strategic workforce planning, and why all three matter What work intelligence actually means in practice, and how decomposing work into tasks is changing how organisations understand the impact of AI on their workforce How AI is actively reshaping roles right now, and what that means for strategic workforce planning, job architecture and redeployment Real-world case studies from organisations using all three signals to make smarter workforce decisions and align their people strategy with their AI strategy What it actually looks like to get started, and why the barrier to entry is lower than most HR leaders think This episode is sponsored by TechWolf. The world of work is being rewritten faster than HR systems can keep up. Skills age in months. Roles get redesigned quarter by quarter. CHROs have quietly become AI transformation leads, and the data they need to lead it doesn't exist in any HR system. That's why the world's most forward-looking enterprises such as HSBC, AMD, T-Mobile, GSK, ServiceNow, Pfizer, have built on TechWolf. As the data layer for the AI era of work, TechWolf gives enterprises the skills, they need to move faster and lead with confidence. Skills Intelligence, Work Intelligence, and Market Intelligence, in one layer. Visit techwolf.ai. Resources: TechWolf podcast Hosted on Acast. See acast.com/privacy for more information.

What does good care actually look like for adults living with sickle cell disease?In this episode of our What Good Care Looks Like for Adults with Sickle Cell series, lifespan sickle cell expert Dr. Julie Kanter focuses on the evolving landscape of sickle cell research and data collection. Dr. Kanter walks through the latest drug development approaches, such as fetal hemoglobin induction and reducing cell adhesion, while highlighting why safe data sharing through national registries is absolutely essential to advancing personalized treatments for the community.Dr. Julie Kanter is the Co-Director of the Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham and President of the ⁠National Alliance of Sickle Cell Centers⁠ (NASCC).This episode is part of Sickle Cell 101's Research 101 Educational Initiative, a community resource dedicated to making care information accessible and actionable for the sickle cell community.Thank you to our Research 101 sponsors: ⁠⁠Agios, Pfizer⁠, and ⁠Beam Therapeutics.

What does good care actually look like for adults living with sickle cell disease?In this episode of our What Good Care Looks Like for Adults with Sickle Cell series, lifespan sickle cell expert Dr. Julie Kanter focuses on navigating treatment options and disease modifiers. Dr. Kanter breaks down the most prominent medications and therapies available today, including hydroxyurea, crizanlizumab, L-glutamine, and blood transfusions, explaining how patients and providers can work together to personalize care and find the best treatment path.Dr. Julie Kanter is the Co-Director of the Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham and President of the ⁠National Alliance of Sickle Cell Centers⁠ (NASCC).This episode is part of Sickle Cell 101's Care and Treatment 101 Educational Initiative, a community resource dedicated to making care information accessible and actionable for the sickle cell community.Thank you to our Care and Treatment 101 sponsors: ⁠Vertex⁠, ⁠Chiesi⁠, ⁠Pfizer⁠, and ⁠Medunik⁠.

Can you really treat prostate cancer effectively without knowing the genetics? In this episode of BackTable Urology, Dr. Evan Yu and Dr. Tanya Dorff join host Dr. Alan Tan to discuss why genetic testing is essential in personalized prostate cancer care. They discuss when and how to perform germline and somatic testing, address common barriers, and share best practices for counseling patients. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction02:18 - Who Gets Somatic Testing?06:43 - Patient Barriers to Testing09:00 - Genetic Testing Workflow12:28 - Treating BRCA2 Alterations24:18 - Monitoring Progression: ctDNA vs. PSA vs. Imaging29:32 - Treating mCRPC with ATM Mutations34:39 - CDK12 Classification 37:43 - Closing Takeaways --- More about this episode The doctors explore how BRCA2 and other DNA repair alterations can directly shape treatment decisions, focusing on the roles of PARP inhibitors and platinum therapy in advanced cases. The discussion highlights why both germline and somatic testing are critical for identifying actionable mutations and discuss the nuances of interpreting test results, including current limitations and emerging biomarkers. They also examine challenges such as insurance coverage, patient misconceptions, and workflow integration, as well as the movement toward truly personalized, biology-driven approaches in prostate cancer care. --- Resources Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial:https://pmc.ncbi.nlm.nih.gov/articles/PMC12705445/ Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study:https://www.annalsofoncology.org/article/S0923-7534(25)04936-1/fulltext Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer:https://www.nejm.org/doi/full/10.1056/NEJMoa1903307 ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patientshttps://www.sciencedirect.com/science/article/pii/S0302283825048766 First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer:https://www.nejm.org/doi/abs/10.1056/NEJMoa2502929 PROMISE Registry:https://www.prostatecancerpromise.org/ Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00683-X/abstract --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of groundbreaking advancements and strategic movements reshaping the landscape of drug development and patient care. Eli Lilly's retatrutide has emerged as a significant breakthrough in obesity treatment, demonstrating a remarkable 30.3% weight reduction over two years in a Phase 3 trial. This drug, a triple agonist targeting glucagon-like peptide-1 receptors, regulates appetite and energy balance effectively. Such results not only highlight its potential as a transformative therapy for obesity but also position Eli Lilly prominently within metabolic disorder treatment landscapes. With global obesity rates on the rise, retatrutide's success could meaningfully impact public health strategies and pharmaceutical approaches to managing weight. In the oncology sector, Johnson & Johnson's acquisition of Firefly Bio for $1 billion is a strategic move aimed at enhancing their oncology pipeline with Firefly's Degrader Antibody Conjugate platform. This technology is designed to target KRAS-driven tumors, which are notoriously difficult to treat, prevalent in cancers such as pancreatic and colorectal cancer. By integrating Firefly's innovative platform, J&J aims to offer new hope for patients dealing with these challenging cancers. Turning to regulatory developments, the FDA has expanded Pfizer's Hympavzi label to include pediatric patients aged six and older with hemophilia A and B. This decision follows robust Phase 3 results that demonstrate Hympavzi's efficacy as a prophylactic treatment in this young population. The expanded label underscores efforts to address pediatric needs in areas traditionally focused on adults, thus broadening treatment options for young patients with bleeding disorders. In Europe, Chiesi's Loxujta (lomitapide) has gained EU pediatric label expansion for treating homozygous familial hypercholesterolemia, supported by strong Phase 3 data. This expansion aligns with a growing trend toward personalized medicine, tailoring treatments to specific genetic profiles even in younger populations. Collaborative efforts in biotechnology are also gaining momentum. GSK has partnered with Engitix to research liver fibrosis regression through extracellular matrix-targeted drug discovery. This collaboration highlights an industry shift towards leveraging biotechnology for innovative therapeutic solutions. Hikma Pharmaceuticals has shown confidence in the U.S. pharmaceutical manufacturing sector by committing $267 million to expand its facilities in Ohio. This expansion enhances Hikma's production capabilities while creating 350 jobs, positively impacting local economies and ensuring robust supply chain capabilities for essential medicines. The clinical trial landscape is vibrant with promising data across various therapeutic areas. Amgen's Repatha (evolocumab) has demonstrated cardiovascular risk reduction in high-risk diabetes patients without prior heart attacks or strokes, reinforcing its role not just in cholesterol management but also in broader cardiovascular risk mitigation strategies. Dexcom has made strides in metabolic diseases with its G7 continuous glucose monitor showing significant benefits for non-insulin-dependent type 2 diabetes patients. This development illustrates the increasing integration of digital health technologies into chronic disease management. Moreover, emerging treatments like Sciwind Biosciences' ecnoglutide have shown superior weight loss outcomes compared to existing therapies such as semaglutide. Such head-to-head comparisons are crucial for advancing competitive therapeutic landscapes and optimizing patient outcomes. In summary, the pharmaceutical and biotech sectors are experiencing transformative changes driven by scientific advancements and strategic collaborations. These developments not only expand treatment options across various therapeutic areas but also signify a shift toward more personalized and integrated healthcare solutions that could significantly impact patient care and drug development pathways globally. As these trends continue to evolve, they will likely drive further progressions in how pharmaceutical companies approach drug development and regulatory engagements, ultimately benefiting patients worldwide through more effective and personalized treatment modalities. Stay tuned for more updates from Pharma Daily as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

TODAY ON THE ROBERT SCOTT BELL SHOW: Vaccine Injury Blindspot, Ryan Richardson, RNC Store, Laetrile/B17, Food System Changes, Franciscea Rheumatic Relief, Pfizer Failed Flu Data, Informed Policy Advocates, California Rights, Ancient Mummy Sourdough, George Washington's Beer and MORE! https://robertscottbell.com/vaccine-injury-blindspot-ryan-richardson-rnc-store-laetrile-b17-food-system-changes-franciscea-rheumatic-relief-pfizer-failed-flu-data-informed-policy-advocates-california-rights-ancient-mumm/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

If you are worried about China taking over due to having better robots than the yanks, I got mixed messages for ya here. This was created using DeepSeek v4 Pro. Remember when DeepSeek could do the same thing as chatGPT but on shitty processors and not much RAM? All those stocks shit themselves? Oh what memories. Would have been a great time to buy NVIDIA stocks. I didn't, if you're asking....It's pretty good but it really didn't follow the instruction in the prompt that Joel Hill is Jack the Insider on the transcript. So that's a minus point. But also, this took fucking ages to generate. It's better than lots of the yankee slop but damn son this took MINUTES. So they might take over if we are patient or whatever. Enjoy the episode. ----------------------------------------------Joel Hill (Jack the Insider) and Hong Kong Jack return for a sprawling episode that tackles two of the biggest stories shaping politics in 2026. The pair open with the jaw-dropping Redbridge poll putting One Nation at 31% of the primary vote — a number that would all but wipe the National Party off the federal map and potentially deliver Anthony Albanese a strengthened majority government by splintering the right. Joel and Jack clash over whether culture-war grievances or material concerns are driving the surge, while drawing historical parallels to Joh for Canberra and the DLP split of the 1950s.The conversation then crosses hemispheres for a tour through UK chaos: Peter Mandelson's leaked dossier exposing a rudderless No. 10 under Keir Starmer, Nicola Sturgeon's estranged husband pleading guilty to embezzling SNP donations on a surreal shopping spree of Lalique salt shakers, seven Dysons, and a motorhome with four miles on the clock, and a deeply troubling police body-cam incident that has reignited the two-tier policing debate ahead of three critical by-elections.The centrepiece of the episode is a sober, hour-long deep dive into the COVID-19 pandemic and what Australia has refused to learn. The Two Jacks lay out the true death toll (perhaps 22 to 69 million globally), the devastating scale of long COVID, the vaccine rollout failures, the absurdities of hotel quarantine with rubbish bags over heads, and why governments and public health officials are desperate to avoid a Royal Commission. They close by asking whether the next pandemic will meet a population that has permanently lost trust in its leaders — and whether we'll simply repeat the mistakes of both COVID and the Spanish flu.Sport provides a lighter coda: the Carlton revival under an interim coach, James Hird's awkward candidacy at Essendon, the expanded 48-team World Cup that nobody seems excited about, and a formidable New Zealand Test side taking on England at Lord's.00:00:25 — Introduction Joel welcomes listeners to Episode 159, recorded 4 June. Today: Australian political news, a check-in on the UK, and a deep dive into the COVID-19 pandemic.00:01:21 — The Redbridge Poll: One Nation at 31% The AFR's Redbridge poll: One Nation 31%, Labor 28%, LNP 20%, Greens 12%. The two-party preferred is now being calculated as One Nation versus Labor — a seismic shift in how Australian politics is measured.00:03:12 — Not Just a Protest Vote Jack argues this is real, not a re-run of Hanson's 1990s flash-in-the-pan. The South Australian state election and the Farrah by-election suggest One Nation support is durable. Joel counters that protest votes can be expressed at the ballot box and that Australians are tiring of pluralism.00:04:09 — If One Nation Succeeds, Labor Wins The cruel irony: One Nation's rise probably delivers Labor government. The National Party could simply disappear. The DLP kept the Coalition in power for decades as an anti-Labor party; One Nation may do the reverse.00:05:46 — Scrutiny and Splintering Joel notes One Nation's policies are "two-sentence fragments" and motherhood statements. When proper scrutiny arrives, the contradictions will surface. Hanson's parliamentary attendance is as poor as imaginable.00:08:22 — The Third Rail Jack argues populists succeed because they discuss what polite society won't: immigration, culture wars, welcome to country rituals. The major parties must engage these topics or cede the ground entirely.00:11:34 — Feeling Unheard The core driver, Jack contends: voters feel sneered at and silenced by mainstream politics. It's not about flag counts, it's about being listened to.00:13:50 — What Actually Drives Votes Joel pushes back: voting determinants are the household economy, migration, climate change — not culture war trivia. Culture wars "don't amount to a hill of beans" at the ballot box.00:14:51 — The DLP Parallel Both agree the One Nation phenomenon most closely resembles the DLP split of the 1950s and 60s — a right-wing fracture that delivered Labor government after Labor government.00:17:18 — The Republic Referendum Lesson Jack recalls the 1999 republic referendum: pro-republicans split between models rather than uniting, scuppering the whole project. Voters will vote their preference even knowing it helps their enemy.00:19:32 — UK Parallels: Accommodate or Fight? Significant figures in the UK Tory party are debating whether to fight Reform or reach an accommodation. Tony Abbott recently said the Liberal Party won't criticise Pauline Hanson.00:21:48 — Joh for Canberra Redux Imre Salusinszky's comparison: this is "Joh for Canberra" all over again. But Joel notes Joh's moment lasted months; One Nation's has already lasted years.00:24:08 — State Election Previews Joel predicts the Victorian state election will be chaotic and peculiar — a government that's been in power too long, an opposition that may not be up to the task, and One Nation peeling votes from safe Labor seats. NSW will give a clearer reading.00:25:44 — Hanson "Ready to Govern" — from the Senate? Pauline Hanson announced she's ready to govern. Joel asks: shouldn't she contest a lower-house seat first? Jack recalls the only precedent: John Gorton became PM while still a senator, but had to be eased into Kooyong.00:28:20 — The Mandelson Dossier: Starmer's Empty Suit Jack's read of the leaked Mandelson documents: ministers don't know what the PM wants, there's zero respect or fear of his authority. Starmer comes across as an empty chair. One minister's text: "Every meeting with Labour MPs — it's all about who can we tax to pay benefits to other people."00:30:50 — Mandelson's Legal Peril Mandelson is under police investigation for misconduct in public office. Could face charges — the seriousness depends on whether it's mere misconduct or genuine bribery for foreign interests.00:31:49 — The Nicola Sturgeon Saga Her estranged husband has pleaded guilty to embezzling roughly £400,000 in SNP donations. The shopping list: six high-end coffee machines, seven Dyson vacuums, Lalique salt and pepper shakers, Montblanc pens, Swiss watches, an iJag, part of a Volkswagen, and a motorhome with four miles on the clock parked at his 92-year-old mother's house. Nicola claims she "didn't go in the kitchen much."00:34:20 — The BBC Interview Laura Kuenssberg's forensic interview with Sturgeon — "not quite Prince Andrew, but not much better." Sturgeon has been cleared by Police Scotland, but her reputation, already damaged by the Alex Salmond trial, is now in tatters.00:35:05 — Will He Go to Prison? £400,000 is a substantial sum. With another £600,000 unaccounted for, a custodial sentence seems likely. The money was ring-fenced for a second independence referendum push.00:36:50 — Money Laundering or Conspicuous Consumption? Joel wonders if the bizarre purchases — multiple watches on the same day — were an amateur money-laundering attempt: buy goods with SNP funds, sell them quietly for cash.00:38:23 — UK By-elections: Makerfield Looms Three by-elections on 18 June, including the critical Makerfield contest. Andy Burnham, Greater Manchester's high-profile mayor, is the tepid favourite. Low turnout could help him return to Westminster.00:39:30 — The Body-Cam Incident A white teenager accused of racially vilifying a Sikh man was stabbed — and police arrested the bleeding victim, not the attacker. Body-cam footage shows the victim saying "I can't breathe, I've been stabbed" while officers dismiss him. Joel calls the footage "just awful."00:41:22 — Two-Tier Policing Jack traces UK policing's overcorrection: after the Macpherson/Lawrence report, guidelines were rewritten so aggressively that they've produced a pattern of questionable enforcement that devastates community trust — and plays directly into Tommy Robinson's hands.00:42:08 — NSW Police on Four Corners Joel recommends the harrowing Four Corners investigation: bashings in custody, false arrests, an officer who threw body-cam footage into Sydney Harbour, and two undercover officers jailed for a savage assault. The problem today is general duties policing, not the specialist squads of the 1980s. Some command areas are far worse than others — a leadership failure.00:44:55 — Victoria Police: Under-Resourced, Not Corrupt Joel shares an anecdote: two divisional vans for 80,000 people in outer-east Melbourne. Tough work being a police officer; even tougher being a good one.The COVID-19 Reckoning00:45:09 — Why This Matters Joel sets the frame: we parked COVID in 2023 with a hangover but never understood what we'd been through. Today's episode aims to crack that problem.00:45:51 — The True Death Toll Officially: 7 million dead. But most countries stopped testing and stopped reporting cause-of-death data to the WHO. Using excess mortality, the real toll is between 22 and 69 million — at the high end, exceeding the Spanish flu.00:47:02 — Long COVID's Shadow Roughly 400 million people globally (6% of the population) have experienced long COVID. In Australia alone, between 200,000 and 500,000 people are living with or have lived with the condition. Second infections can be worse. Emerging links to cardiovascular disease, type 2 diabetes, and accelerated dementia.00:49:43 — The Collective Amnesia Governments worldwide have "a collective embarrassment" about how they handled the pandemic, Jack says. They want it in the history books and forgotten. Joel says this is a grave mistake for public trust — and for public health, given COVID is now a permanent fixture alongside flu season.00:50:50 — Why Excess Deaths Are the Only Honest Metric All other figures are "kind of made up" because attribution methods vary wildly between countries. Excess deaths remain elevated in Australia and most nations.00:51:25 — Children and COVID Bobby Kennedy Jr. removed under-18s from government-supported vaccines in the US. Joel argues this is a disastrous move given mounting evidence that childhood COVID infection leads to higher rates of long-term chronic illness.00:52:47 — Why No Royal Commission? Not just politicians protecting themselves — public health officials and much of the media wanted to avoid scrutiny of their judgments and actions during the pandemic.00:53:32 — The Media's Abdication Jack watched "a lot" of Daniel Andrews's daily press conferences. Only two journalists ever asked pertinent questions: Rachel Baxendale and Leigh Sales. Nobody asked why curfews, why beach arrests, why the disparate impact on tradies and cafe owners while the "laptop class" actually made money working from home.00:56:14 — Andrews's Immense Popularity Joel adds context: Andrews was wildly popular at the time, which partly explains the media's deference — though Jack insists that shouldn't have mattered.00:57:34 — The Curfew Nonsense Curfews were about giving law enforcement the easiest possible environment, Joel says — and should have been acknowledged as such and wound back sooner. Meanwhile, Bondi's wealthy swam en masse while Western Sydney's working-class communities were treated harshly.00:57:59 — The Vaccine Rollout Failure The Morrison government bet everything on AstraZeneca — the non-mRNA, first-available vaccine. Then rare blood-clotting issues emerged (seven deaths, mainly men aged 40–49). Meanwhile, Australia was left waiting for Pfizer and other mRNA vaccines because no other supply deals had been secured.00:59:37 — Omicron Breaks the Pandemic's Back The Omicron variant emerged from South Africa: more infectious but far less lethal. Combined with 95%+ vaccination rates among Australians over 18, it effectively ended the acute phase — though at the cost of entrenched mistrust.01:00:38 — Government Overreach and Broken Trust Jack's core criticism: governments outsourced decision-making to public health officials rather than making political judgments that balanced competing interests. Joel counters that it would have been a "bold move" for politicians with no scientific background to contradict public health advice.01:02:19 — "Just Let It Rip" Was Never an Option The three countries with the highest COVID mortality — Brazil (highest), United States (second), India (third) — were all led by populist governments that largely refused mandates. Letting it rip was devastating.01:03:27 — The ADF Quarantine Scandal Scott Morrison refused to allow ADF quarantine facilities to be used for returning travellers. Instead, people were crammed into hotels with gaps under the doors. Joel recalls the "rubbish bags over heads" episode in Victoria — dark green plastic bags as infection control.01:05:00 — The Inquiry's Recommendations Create a proper Australian CDC. Release expert advice publicly. Better national planning with clear political accountability. And critically: politicians must own the big decisions on freedoms and spending instead of hiding behind experts.01:06:01 — The Next Pandemic There will be another one. If it's a respiratory, airborne pathogen like COVID, similar circumstances will return. Are we ready? Probably not. Will we close the country again? The economic damage — unemployment hitting 7.5% in 2020 — was enormous, even if it recovered to 3.5% by pandemic's end.01:08:06 — Who Was Left Behind? The arts community was inexplicably excluded from JobSeeker and JobKeeper. Meanwhile, the "laptop class" working from home effectively got a 15% pay rise by eliminating commuting costs. Bunnings did very well; so did companies that kept JobKeeper without passing it to employees.01:11:14 — The Human Cost of Lockdowns Public housing towers in Flemington were locked down. Joel recalls one family: an African-Australian single mother with nine children in a two-bedroom commission flat, trapped. Jack calls what happened with schools "disgraceful." But Joel notes the evidence now shows childhood COVID infection has serious long-term health consequences, complicating the retrospective judgment.01:13:59 — Will We Learn Anything? Jack's bleak prediction: the next pandemic is probably far enough away that we'll take no notice of COVID's lessons and make the same mistakes. Joel agrees — we didn't learn from the Spanish flu a century ago either.01:15:51 — Malcolm Roberts and Vaccine Misinformation The One Nation senator claims 70,000 Australians died from COVID vaccines — a figure with no evidentiary support, built by misattributing excess deaths. In reality, mRNA technology is now being deployed as a cancer treatment, showing promise against bowel and pancreatic cancers.01:17:36 — Trust Destroyed If the next pandemic arrives within this generation, governments will face a population that has lost faith. If it takes 50 years, the damage may have faded. Western Australia, meanwhile, locked itself down with negligible deaths and actually loved the isolation — provided the iron ore and LNG ships kept moving.01:20:37 — The Spanish Flu Echo Joel's closing historical note: Australia's response to the Spanish flu in 1919–1921 was nearly identical to COVID — lockdown disputes, police arresting people for not wearing masks, states fighting the newly created federal Department of Health. The whole thing collapsed into acrimony the moment state rivalries flared. A century later, nothing had changed.01:21:48 — Federation as Fatal Flaw Jack adds: the three high-mortality COVID countries (US, Brazil, India) share a feature beyond populist leaders — they're all federations where central government power is limited. When "the emperor is far away and the mountains are high," coordinated pandemic response is nearly impossible.01:23:40 — No Appetite for Truth Jack's final word: nobody wants a proper inquiry. Not politicians, not public health officials, not much of the media. Joel disagrees on the importance — the pandemic's legacy still shapes how Australians think, vote, and trust.Sport01:27:40 — AFL Coaching Carousel Essendon and Carlton both need permanent coaches. Joel asks: is James Hird the right man for Essendon? Jack: 17 other clubs wouldn't give him an interview, but the Bombers may have backed themselves into a corner where appointing him is the only way out.01:28:53 — Merit vs Member Sentiment Rowan Connolly's question: would you take James Hird or John Longmire (five grand finals, one premiership, 60%+ win rate)? The answer is obvious on merit — but members and fans want the fairy tale.01:29:47 — Carlton's Astonishing Revival Three straight wins. Ranked 16th in forward-50 entries a month ago; now second. The game style is unrecognisable — no more bombing the ball to non-existent power forwards. Mitch McGovern's low, flat kick to Patrick Cripps for the match-winner against Geelong was emblematic of the transformation. Seven players aged 21 or younger are now getting games and bringing energy.01:33:18 — FIFA World Cup 2026: Nobody's Excited Expanded to 48 teams, Scotland are going — and a Scot in his 30s told Jack that neither he nor any of his mates (all doing well financially, normally first on the plane) have any interest. Ticket prices are "extraordinary." The final is at MetLife Stadium in New Jersey — which Jack describes as "Waverley on steroids, but even more bleak."01:36:08 — Australia's Draw Socceroos face Turkey first up, then the United States. Jack suggests marketing it as "Gallipoli Round Two." Spain are favourites; England, Brazil, and Germany are in the chasing pack.01:37:06 — Cricket: England v New Zealand, First Test at Lord's Joel runs through New Zealand's likely top seven — Latham, Conway, Williamson, Ravindra, Mitchell, Blundell — noting the first four have all made Test double-centuries. "Just about the best first six in Test cricket." With O'Rourke's express pace and Henry's quality, this is a formidable Black Caps side.01:38:40 — Stump Speech & Next Week Listener mail (including an "exposé of who Jack is") held over for next episode. For the record: Hong Kong Jack's CV includes HSC at Assumption College Kilmore, a stint as a carpenter, a law degree from Melbourne University, stints at Holding Redlich and Slater & Gordon, work as a litigation and immigration lawyer, and an appointment to the Refugee Review Tribunal as a federal cabinet appointee.01:40:39 — Outro Joel thanks listeners for hanging in for an extra ten minutes. Back next week.The Two Jacks is recorded weekly. Send your questions and feedback to the show.

Join us on The Sean Spicer Show as we dive deep into the latest political news, offering sharp news analysis on current events like Pfizer reform, the budget, and the 2028 midterms. We explore various aspects of us politics with guests like Majority Whip Tom Emmer and Dave Rubin, fostering a robust political discussion. This episode provides an in-depth political debate from a conservative vs liberal perspective. https://www.seanspicer.com subscribe for an ad free version of this podcast Boll & Branch - https://www.bollandbranch.com/SPICER for 15% OFF and FREE SHIPPING Ruffgreens - https://ruffgreens.com/⁠ enter code: SPICER for your FREE starter pack Market Institute - https://www.MarketInstitute.org - Check them out today Learn more about your ad choices. Visit megaphone.fm/adchoices

Let us know what you think of the show and what we can do better! Orders are supposed to be clear, lawful, and tied to mission. So what happens when a policy feels wrong in your gut, looks shaky in the paperwork, and gets enforced with threats, segregation, and career-ending consequences?I'm joined by Scott Lauderer, a retired Air Force reservist with 25 years of service across multiple branches, and former Army Sergeant First Class John Eugene Delarm, a combat veteran separated near retirement. We get specific about what they say unfolded during the military COVID-19 vaccine mandate: formations and “shot lines,” religious accommodation denials, repeated pressure from leadership, and the kind of retaliation that leaves troops feeling isolated and disposable. They also share why they believe protecting junior service members is part of the NCO and leader's duty, even when the personal cost is brutal.John walks through the EUA argument in plain terms, including the Comirnaty vs Pfizer confusion and why 10 USC 1107a matters to the right to accept or refuse an Emergency Use Authorization product. From there, we zoom out to military accountability: what courts did and didn't address, why many veterans still chase BCMR corrections and back pay, and why reinstatement offers can feel like a fix with strings attached. We also talk about the Declaration of Military Accountability, the Forgotten Soldiers podcast, and the documentary Duty to Disobey, premiering June 30, that centers the human stories behind the mandate era.If this conversation challenges you, share it with someone who thinks the debate is “over,” then subscribe, leave a review, and tell me: what should accountability actually look like now?Stories of Service presents guests' stories and opinions in their own words, reflecting their personal experiences and perspectives. While shared respectfully and authentically, the podcast does not independently verify all statements. Views expressed are those of the guests and do not necessarily reflect the host, producers, government agencies, or podcast affiliates.Support the showVisit my website: https://thehello.llc/THERESACARPENTERRead my writings on my blog: https://www.theresatapestries.com/Listen to other episodes on my podcast: https://storiesofservice.buzzsprout.comWatch episodes of my podcast:https://www.youtube.com/c/TheresaCarpenter76

America Out Loud PULSE with Dr. Peter McCullough and Malcolm Out Loud – Can a person get Myocarditis 2 years after the shot, even if they don't have it within a few weeks after the shot? Should people who are unvaccinated, like my wife, not be intimate with vaccinated individuals, like myself, 3-4 years post Pfizer vaccine? What are coatings around supplements and capsules made of?

As concerns escalate about the deadly Ebola virus outbreak in Africa, we bring you the unique insights of Dr. Peter Piot, a renowned microbiologist who co-discovered the virus 50 years ago during the first recorded outbreak of the disease. His on-the-ground account of that crisis was provided to us in April before the current outbreak was declared, but it contains valuable historical perspective and shares lessons learned that he carried forward in his consequential career.  “What I saw from the beginning is the most important thing is to listen to people and that you need to act fast to save lives, before you have the evidence you would like to have.”    He followed his contributions on Ebola by diving into the fight against HIV/AIDS, eventually reshaping global response in leadership roles at the World Health Organization and United Nations. As he shares with host Lindsey Smith, the learnings in that case were more pragmatic than scientific. “We had to redefine HIV/AIDS not as a medical problem but as an economic and security problem in order to get it on the political agenda.”  Tune in for a fascinating episode that takes you from the gritty frontlines of public health crises to the battles for funding and attention in the halls of power as Dr. Piot shares what it actually takes to move the world to respond effectively to health threats. Mentioned in this episode: London School of Hygiene & Tropical Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

What does it take to turn a 300-year-old bank into the UK's biggest fintech? Sharon Doherty is Chief People and Places Officer at Lloyds Banking Group, and over the last four years she's been leading one of the most ambitious organisational transformations in British financial services - 300-year-old institution reinventing itself as the UK's biggest fintech.In this episode, David and Sharon get into what transformation at that scale actually looks like from the inside - the governance, the culture work, the AI strategy, and the tough calls that only leadership can make. How Sharon thinks about her role as CPPO through three lenses: storyteller, tough lover, and disruptorThe AI governance structure at Lloyds, including the control tower she runs with the CTO and the ethics committee underpinning every decisionThe cross-functional super agent Lloyds is building with MicrosoftWhy HR leaders should be fighting to get Places on their remit, and how ownership of the physical environment transforms what the function can deliverHow Lloyds is approaching the shift from AI literacy to AI fluency across 80,000 peopleWhat Sharon thinks the world of work looks like in 2033, and the role HR must play in getting there This episode is sponsored by TechWolf. The world of work is being rewritten faster than HR systems can keep up. Skills age in months. Roles get redesigned quarter by quarter. CHROs have quietly become AI transformation leads, and the data they need to lead it doesn't exist in any HR system. That's why the world's most forward-looking enterprises such as HSBC, AMD, T-Mobile, GSK, ServiceNow, Pfizer, have built on TechWolf. As the data layer for the AI era of work, TechWolf gives enterprises the skills, they need to move faster and lead with confidence. Skills Intelligence, Work Intelligence, and Market Intelligence, in one layer. Visit techwolf.ai. Hosted on Acast. See acast.com/privacy for more information.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways:

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways: